Our Projects - THE experience we share!
Since the foundation of the first research and innovation agency EUrelations AG in Switzerland, our team has been involved in building several hundred research consortia. As a result, we have been able to gain considerable knowledge and continuously acquire new methodological skills. Here are some interesting extracts from our work over the past 15 years:
AcceleRare is the collaborative response of the Swiss research community to the National Rare Disease Policy. Our common goal is to use cutting-edge academic science and a unique project management structure to develop new drugs and therapies, while addressing related societal challenges. As AcceleRare, we apply as a National Centre of Competence in Research for a federal mandate to advance drug discovery for rare diseases.
Who are we?
AcceleRare is a Swiss academic research consortium of 28 research groups from 12 institutions, led by the University of Zurich, ETH Zurich, and the University of Geneva.
Why this collaboration?
Rare diseases, which affect around half a million people (mostly children and young adults) in Switzerland, pose an underestimated threat to human health. The challenge is to investigate these diseases, understand their mechanisms, and develop individual therapies. We apply state-of-the-art expertise and technologies to advance rare disease research in harmony with those affected.
In December 2018, AcceleRare applied to the Swiss National Science Foundation for funding as a National Centre of Competence in Research (NCCR). Upon initial evaluation by external experts, the proposal received excellent reviews and by now we have made it to the final stages of the selection procedure after another round of positive assessments and interviews. If AcceleRare gets approved, it will create a knowledge platform for rare disease research while strengthening (inter)national collaboration between researchers, pharmaceutical industry, and patient advocacy groups. We aim to:
Investigate disease mechanisms, develop new innovative treatments;
Accelerate clinical translation and technology transfer, including ethical, legal, and organisational aspects of rare disease research;
Stimulate knowledge exchange between multi-disciplinary academic research teams, pharmaceutical industry, and patient advocacy groups;
Provide cutting-edge education and training in a restructured research field
NCCR AcceleRare capitalizes on recent developments in personalized medicine, digitization, translational research, and health economics to address societal challenges resulting from rare diseases. Implementation of this NCCR will provide:
Novel insights in disease mechanisms, potentially relevant to common diseases;
Innovative drugs and treatments for rare disease patients;
Policy and decision-making concepts for societal challenges of rare diseases;
Effective knowledge transfer between academia, industry, and society;
Experts prepared for a career in academia, industry, or public service;
a world-leading position for Switzerland in rare disease research.
The AcceleRare network stimulates structural measures, translational & entrepreneurial initiatives, an education and training portfolio, integration into competence centres, and exchanges with patients and society. Together, this will ensure a long-lasting impact and turn Switzerland into a lighthouse for translational rare disease Research.